Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00062647
Status:
COMPLETED
Last Update Posted:
2019-01-16
First Post:
2003-06-09
Brief Title:
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
Sponsor:
Cumberland Pharmaceuticals
Organization:
Cumberland Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Parallel-Group Multinational Trial of Intravenous Televancin TD-6424 for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ASSURE
Brief Summary:
The purpose of this study is to determine whether telavancin TD-6424 ARBELIC can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None